The overall objective of this grant is to both define and confirm the genetic contribution to the large inter-individual variability in clinical response to treatment with statin drugs. The multidisciplinary research team has expertise in genomics, statistical genetics and informatics, clinical pharmacology and cardiology, laboratory measurements of cardiovascular risk factors, and epidemiology. In a sequential design, using samples from a total of 10,000 subjects treated with various statins, we will use a genome wide association approach to identify SNPs (single nucleotide polymorphisms) that are associated with laboratory measurements of statin response, including LDL and HDL subfractions, markers of cholesterol absorption and synthesis, and the inflammatory marker hs-CRP. Initial analyses in 1,000 Caucasian subjects from trials of simvastatin or pravastatin will be based on a panel of 250,000 genome-wide SNPs (Aim 1). Confirmatory analyses in cohorts treated with rosuvastatin (Aim 2) and atorvastatin (Aim 3) will yield a panel of 1,100 SNPs most consistently associated with variation in statin response of LDL cholesterol and other phenotypes in Caucasians and African-Americans. In addition, the genome-wide SNP panel along with candidate gene SNPs will be used to identify those associated with statin-related myopathy in 150 cases vs. 300 matched controls. Genomic resequencing of the 50 genes most strongly associated in Aims 2 and 3 with statininduced reductions in LDL cholesterol and other informative phenotypes will identify allelic variants in a total of 48 Caucasians and 48 African-American randomly selected from the highest and lowest 5% of the distributions of these phenotypes in the respective ethnic groups (Aim 4). Finally, these SNPs will be tested for associations with both laboratory phenotypes and clinical cardiovascular outcomes (Aim 5). This program presents a comprehensive approach for determining effects of specific genotypes on clinically meaningful variations in responsiveness to a class of drugs widely used to prevent cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HL069757-08S1
Application #
7686432
Study Section
Special Emphasis Panel (ZRG1-GGG-B (50))
Program Officer
Srinivas, Pothur R
Project Start
2001-09-27
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
8
Fiscal Year
2008
Total Cost
$83,336
Indirect Cost
Name
Children's Hospital & Res Ctr at Oakland
Department
Type
DUNS #
076536184
City
Oakland
State
CA
Country
United States
Zip Code
94609
Lee, Seung-Been; Wheeler, Marsha M; Patterson, Karynne et al. (2018) Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med :
Theusch, E; Kim, K; Stevens, K et al. (2017) Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. Pharmacogenomics J 17:222-229
Feng, Q; Wei, W Q; Chung, C P et al. (2017) The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J 17:204-208
Elbadawi-Sidhu, Mona; Baillie, Rebecca A; Zhu, Hongjie et al. (2017) Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Metabolomics 13:
Gordon, Adam S; Fulton, Robert S; Qin, Xiang et al. (2016) PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet Genomics :
Norby, Faye L; Eryd, Samuel Adamsson; Niemeijer, Maartje N et al. (2016) Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium. PLoS One 11:e0151932
Hall, Kathryn T; Jablonski, Kathleen A; Chen, Ling et al. (2016) Catechol-O-methyltransferase association with hemoglobin A1c. Metabolism 65:961-967
Ehret, Georg B (see original citation for additional authors) (2016) The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet 48:1171-1184
Mora, Samia; Caulfield, Michael P; Wohlgemuth, Jay et al. (2015) Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvasta Circulation 132:2220-9
Luzum, Jasmine A; Theusch, Elizabeth; Taylor, Kent D et al. (2015) Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. J Cardiovasc Pharmacol 66:80-5

Showing the most recent 10 out of 106 publications